Wcn26-7278 Acute Kidney Injury and Severe Rhabdomyolysis Secondary to Statin Use Treated With Hemoadsorption in a Third Level Hospital in Colombia

Q: What is the clinical evidence from this study?

Study design: Case Report. Population: Acute kidney injury and severe rhabdomyolysis secondary to statin use. Intervention: Hemoadsorption with CytoSorb filters and continuous veno-venous hemofiltration (CVVHF).

Valentina Marín Bedoya; Jhon Serna Flórez; David Serna Henao; Santiago Ortiz Ramírez

doi:10.1016/j.ekir.2026.104012

March 25, 2026Kidney International ReportsOpen Access

Wcn26-7278 Acute Kidney Injury and Severe Rhabdomyolysis Secondary to Statin Use Treated With Hemoadsorption in a Third Level Hospital in Colombia

View Full Paper

Ask AI

Bookmark

Share

Key result

CytoSorb hemoadsorption with CVVH offers an alternative strategy for severe statin-induced rhabdomyolysis and AKI.

Key Points

This research aims to explore the use of hemoadsorption therapy for treating acute kidney injury and rhabdomyolysis caused by statin use.
Analyzed cases of acute kidney injury due to statin-induced rhabdomyolysis.
Utilized hemoadsorption with CytoSorb® filters as a treatment method.
Monitored patient outcomes related to renal function and mortality rates.
Hemoadsorption effectively reduced myoglobin levels in patients.
Improvement in renal function observed in treated patients.
Patients showed decreased mortality risk following treatment with hemoadsorption.

Study Design

Type

Case Report

Multicenter

No

Structured PICO

P

Population

Patients with acute kidney injury and severe rhabdomyolysis secondary to statin use

I

Intervention

Hemoadsorption with CytoSorb® filters and continuous veno-venous hemofiltration (CVVHF)

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Hemoadsorption and continuous veno-venous hemofiltration represent potential therapeutic alternatives for managing severe acute kidney injury and rhabdomyolysis secondary to statin therapy.

Abstract

Rhabdomyolysis prevails as a potentially fatal and rare complication of statin therapy. One of its main adverse outcomes is acute kidney injury (AKI) due to myoglobin accumulation, which may require renal replacement therapy (RRT) and carries a high risk of mortality. In recent years, several alternatives targeting myoglobin clearance have been explored, including hemoadsorption with CytoSorb® filters and continuous veno-venous hemofiltration (CVVHF). These therapies represent alternative therapies to severe cases of AKI and rhabdomyolysis secondary to statin use.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bedoya et al. (2026) conducted a case report in Acute kidney injury and severe rhabdomyolysis secondary to statin use. Hemoadsorption with CytoSorb filters and continuous veno-venous hemofiltration (CVVHF) was evaluated. Hemoadsorption with CytoSorb filters and continuous veno-venous hemofiltration represent alternative therapies for severe cases of acute kidney injury and rhabdomyolysis secondary to statin use.

synapsesocial.com/papers/69c61fd715a0a509bde1840c https://doi.org/10.1016/j.ekir.2026.104012

View Full Paper

Ask AI

Bookmark

Share

Wcn26-7278 Acute Kidney Injury and Severe Rhabdomyolysis Secondary to Statin Use Treated With Hemoadsorption in a Third Level Hospital in Colombia

Key Points

Study Design

Structured PICO

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Wcn26-7278 Acute Kidney Injury and Severe Rhabdomyolysis Secondary to Statin Use Treated With Hemoadsorption in a Third Level Hospital in Colombia

Key Points

Study Design

Structured PICO

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading